by guest www.bloodjournal.org From Higher levels of procoagulant factors, and factor XII deficiency, may be risk factors for first venous thromboembolism (VTE). We studied associations of coagulation factors IX through XIII with risk of future VTE in two general population samples. Using a nested case-control study combining the 21,860 participants of the Atherosclerosis Risk in Communities study and the Cardiovascular Health Study, we determined antigenic levels of these coagulation factors in primarily pre-event blood samples from 462 participants who subsequently developed VTE and 1,047 participants who remained free of VTE. Only elevated levels of factors IX and XI were associated with increased risk of VTE after adjustment for age, sex, race and study. For factor IX the odds ratio (OR) was 1.4 (95% CI 1.0-2.0) comparing the top to bottom quintile. The OR for factor XI was higher, 2.0 (95% CI 1.4-2.9). With further adjustment for body-mass index and diabetes, only elevated factor XI remained associated with VTE risk, OR 1.8 (95% CI 1.3, 2.7). Associations were similar by study and whether the thrombosis was idiopathic or secondary. Factor XII deficiency was not related to VTE risk. Among these procoagulant factors, only elevated factor XI was a risk factor for VTE.
Introduction
Venous thromboembolism (VTE) is a common vascular disease tied etiologically to the balance between the endogenous procoagulant and anticoagulant systems. Several studies have confirmed that higher levels of factor II, V and VIII are associated with VTE risk 1 . Associations of factor VII and fibrinogen with VTE are less consistent 1 studies, which are both case-control studies. LETS reported higher VTE risk in persons in the upper parts of the population distributions of factors IX 2 ; X 3 and XI 4 ; but not factor XII 5 . Other reports suggest factor XII deficiency is related to risk of first or recurrent thrombosis [6] [7] [8] [9] and, although findings have been inconsistent 5, 10 . An inverse association of factor XIII (activity and the Val 34
Leu polymorphism) with VTE has been reported, although results for the factor XIII gene variant have been mixed 11, 12 . In a study of postoperative asymptomatic DVT, higher factor VIII, but not factors VII or IX, were associated with DVT risk 13 .
Confirmation of these results in other populations, preferably in prospective studies, is important for several reasons. Most published data on procoagulant factors and risk of DVT are from two Dutch studies in which blood samples were obtained after the VTE, most results have not included adjustment for obesity (a major VTE risk factor), there is little data concerning pulmonary embolus, and many clinicians measure some of these factors in patients with thrombosis 14 . It is unclear that such measurements are clinically useful. Here, we report results on associations of levels of coagulation factors IX through XIII with risk of future VTE in the Longitudinal Investigation of Thromboembolism (LITE). We hypothesized that low levels of factor XII (Hageman factor) and
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From high levels of factors IX, X, XI and XIII would be risk factors for VTE, and that these would add to the risk associated with other VTE risk factors. We previously reported associations of higher FVIII and von Willebrand factor with greater VTE risk in this prospective study 15, 16 .
Methods

Subjects
The LITE consists of participants of the Cardiovascular Health Study (CHS) and the Atherosclerosis Risks in Communities (ARIC) study 17 , population-based observational studies examining risk factors for cardiovascular diseases in six US communities 18, 19 . In 1987-89, 15,792 men and women aged 45-64 were enrolled in ARIC; 27% were African American. In 1989-90, 5,201 men and women aged 65-100 were enrolled in CHS. An additional 687 African-American participants were enrolled in CHS in 1992-93. All participants provided written informed consent with methods approved by institutional review committees at all participating institutions, in accordance with the Declaration of Helsinki.
Baseline risk factor data included medical history and measured height and weight. Body-mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Race was categorized as African-American or white based on participant self-identification. Diabetes was defined as fasting glucose ≥ 126 mg/dL, non-fasting glucose ≥ 200 mg/dL or use of diabetes medication. The ARIC participants were followed by clinic visits every 3 years, annual telephone calls, and surveillance of community hospitals. The CHS participants were followed with alternating clinic visits and telephone calls every 6 months. Clinic visits ended in 1998 for ARIC 17 . VTE events required a positive duplex or Doppler ultrasound or venogram, high probability ventilation-perfusion scan or positive chest computed tomography.
Cases were classified as incident (no self-reported VTE history before baseline) or recurrent (selfreported VTE history before baseline), and as secondary (associated with active cancer, or within 90 days of major trauma, surgery or marked immobility such as coma, paralysis, or orthopedic-induced limitation) or idiopathic (not associated with the prior risk factors) 17 .
A nested case-control study design was used to evaluate associations of coagulation factor levels and VTE. We randomly selected two controls, frequency-matched to VTE cases by 5-year age group, gender, race, follow-up time, and study (ARIC, CHS). Controls had not had VTE as of the selected follow-up date. Baseline blood samples were retrieved from storage freezers for cases and controls.
When sample availability was limited, samples were retrieved from a later blood collection, almost always before events occurred. Of 548 cases and 1097 controls, 1520/1645 had sufficient blood samples for analysis and 18 using warfarin at baseline were excluded. Of the remaining 1502 participants, seven who were selected as controls later developed VTE and were included in the analysis as both a control and a case. The analysis included 462 VTE cases and 1047 controls.
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Laboratory Methods
Blood was drawn in the morning after an overnight fast at baseline and three years later in both studies, and 7 years later in ARIC. Samples were centrifuged at 4°C for 30,000g-min, and stored in -70°C or colder freezers. Baseline factor VIII coagulant activity (VIIIc) was measured by one-stage clotting assays during enrollment in all participants except the additional CHS African-American cohort 20, 21 . In the nested case-control sample, factors IX, X, XI, XII and XIIIA subunit antigenic levels were measured in citrate plasma by sandwich enzyme-linked immunoassays using reagents with affinity purified polyclonal antibodies from Enzyme Research Laboratories (South Bend, IN).
Assays were rarely done using post-VTE event blood samples. Coefficients of variation for control samples with 100% levels were 5.4%, 4.9%, 6.8%, 5.0% and 6.9%, respectively. D-dimer was measured by immunoturbidometric analysis on the STA-R instrument (Liatest D-dimer, Diagnostica Stago). Factor V Leiden and prothrombin 20210A genotypes were determined by standard methods.
Statistical Analysis
Coagulation factor levels were the independent variables and their associations with each other and covariates of interest were examined using Spearman correlation coefficients or Wilcoxon rank sum tests. Coagulation factor levels were then categorized into quintiles and were also dichotomized (at the 60 th percentile for factor XII deficiency (~2.5 th percentile) and at the top decile for the other factors). Factor VIIIc and D-dimer were categorized as abnormal based on prior studies as levels in the top quartile and top tertile, respectively 15, 22 . Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Robust variance estimates were used to account for data from the seven controls who later became cases. Models examined each coagulation factor separately, first adjusting for age, sex, race and study, then also adjusting for For personal use only. on October 31, 2017. by guest www.bloodjournal.org From baseline body-mass index and diabetes status, which were risk factors for VTE in LITE. Separate models were fit adding factor VIII level. Analyses were repeated in subsets (idiopathic vs secondary VTE and ARIC vs CHS). Additive interactions among elevated coagulation factors that were associated with VTE risk were assessed by estimating odds ratios after cross-classifying participants by each pair of factors, then calculating the relative excess risk due to interaction (RERI) percent, the percentage of disease attributable to the joint exposure 23, 24 .
Results
Baseline coagulation factor levels and characteristics of the 462 participants who developed VTE and 1047 who did not are shown in table 1. Those who developed VTE had a higher mean bodymass index than those who did not and were more likely to have diabetes. Cases had higher mean levels of factors IX and XI than non-cases. Among the 462 VTE cases, 196 were idiopathic, 314
were DVT and 148 were PE +/-DVT. Table 2 shows the interrelations of coagulation factors and VTE risk factors at baseline among participants who remained free of VTE. The coagulation factors were modestly correlated with each other, in particular the vitamin K dependent factors, factors IX and X, which were also each modestly associated with factor XI. Factor XII was most closely associated with factor X, and factor XIII was moderately correlated with factors IX, X and XI. Factor VIIIc was most strongly correlated with factor IX, but this association was weak to moderate (Spearman correlation coefficient 0.19). D-dimer was only correlated with factor IX, though weakly. Body-mass index was only higher with higher levels of factor IX, and to a lesser extent, factor X. All of the coagulation factors were higher in women than men, with the largest gender difference for factor XII. Older age was associated with For personal use only. on October 31, 2017. by guest www.bloodjournal.org From higher levels of factors IX and XIII, and lower levels of factors X, XI and XII. Coagulation factor levels did not differ by factor V Leiden or prothrombin 20210 genotype. Figure 1 shows the odds ratios of VTE by quintiles of each coagulation factor, adjusted for age, sex, race and study. VTE risk was higher with increasing levels of factors IX and XI, but not for the other factors. For factor IX the odds ratios (95% CIs) for the 4 th and 5 th quintile were similar at 1.3 (0.9-1.9) and 1.4 (1.0-2.0), relative to the first quintile. Results were similar comparing the top decile to all lower values: OR 1.4 (1.0-1.9). Factor XI had more of a graded increase in risk with each increasing quintile, with odds ratios in the 3 rd , 4 th and 5 th quintiles of 1.3 (0.9-1.9), 1.4 (1.0-2.1) and 2.0 (1.4-2.9), respectively. The odds ratio for the top decile of factor XI compared to all lower values was 1.3 (0.9-1.8). Similar odds ratios were found for the top decile of factors X and XIII compared to all lower values, at 1.3 (0.9, 1.8) for each. Results for factors X, XII and XIII are shown in detail in Web Table 1 . Results for all coagulation factors were nearly identical after exclusion of 37 cases self-reporting pre-baseline VTE, or of 51 cases and 30 controls who self-reported a history of VTE at baseline (data not shown). Table 3 shows the impact of added adjustment for BMI and diabetes on the odds ratios of VTE associated with factors IX and XI. In these models, the positive association of factor IX level with VTE was attenuated to the null (primarily by adjustment for BMI), but the association of higher factor XI with VTE remained strong. For factor IX, adjusted odds ratios were similar for idiopathic and secondary VTE, and in each cohort. Odds ratios for factor XI in the top quintile relative to the first were similar for idiopathic and secondary VTE, and were slightly higher in the older CHS cohort (2.2; 1.2-4.0) than in ARIC (1.7; 1.0-2.7). The adjusted odds ratios for factor XI in the top quintile were higher in relation to risk of PE +/-DVT (2.4; 1.3-4.4) than DVT alone (1.7; 1.1-2.5).
Odds ratios also did not differ considering only participants with a first time VTE. For both factors, results were null when comparing values above versus below the 90 th percentile (factor IX >184%, factor XI >176%). Exclusion of those with obesity or diabetes from analysis did not alter interpretation of the findings for either factor. For factors IX and XI, results were similar for cases occurring within compared to one year after factors were measured.
For factor X, adjustment for BMI and diabetes attenuated the odds ratios for values above the 90 th percentile (data not shown). Odds ratios were similarly null for idiopathic and secondary VTE and by study. For Factor XIII above the 90 th percentile there was no impact of adjustment for BMI and diabetes, and results for idiopathic or secondary VTE and by study were similar to the overall analysis (data not shown).
There was no evidence of higher risk of VTE with factor XII deficiency. Participants with levels below 60% compared to higher levels had an adjusted odds ratio of VTE of 0.9 (0.5, 1.7). This was 0.7 (0.3, 1.9) for idiopathic VTE and 1.1 (0.5, 2.3) for secondary VTE.
Factors IX and XI were modestly directly correlated with factor VIIIc (table 2). In models adjusting for age, sex, race, diabetes, body-mass index and factor VIIIc level, the odds ratios associated with factors IX and XI in the top versus bottom quintile were 1.0 (0.6, 1.4) and 1.6 (1.1, 2.4), respectively. The adjusted odds ratio per one standard deviation higher factor VIII and factor IX were 1.4 (1.2, 1.6) and 1.2 (1.0, 1.3), respectively, while the odds ratio for Factor VIII in the top quintile was 2.1 (95% CI 1.4, 3.0).
The odds ratio of VTE for D-dimer in the top tertile compared to the bottom tertile, adjusted for age, race, sex, study, BMI and diabetes was 2.0 (1.5, 2.7). The OR for the top versus bottom quintile of factor XI adjusting for these factors plus D-Dimer was 1.8 (1.2, 2.6). In table 4, elevated factor XI did not interact on more than an additive scale with other VTE risk factors.
Discussion
The main finding of this prospective epidemiologic study is that among several procoagulant factors (IX though XIII) only elevated factor XI was independently associated with increased risk of future VTE. This association was not confounded by levels of factor VIIIc or D-dimer, which were strong VTE risk factors in this study 15, 22 . The association was slightly weaker than for factor VIIIc. This association was similar for idiopathic and secondary VTE and among younger and older participants, but was stronger for PE than DVT. Factor XII deficiency was not associated with increased VTE risk. Elevated factor XI added to the risk associated with some other risk factors, but interactions beyond additivity were not significant.
Other than factor XII, there are few studies assessing these procoagulant factors in relation to VTE risk. Our finding for factor XI agrees with the LETS and MEGA findings, which suggested a 2.3 and 1.9-fold increased risk of VTE, respectively, with higher levels, after adjustment for age, sex and oral contraceptive use (the latter assessed in LETS only). Gene discovery studies have confirmed that variation in the factor XI gene was associated with VTE risk 25, 26 , and the polymorphisms in both studies were in strong linkage disequilibrium. In the LETS and MEGA studies this gene variation was associated with factor XI levels and adjustment for factor XI weakened, but did not eliminate the excess risk associated with gene variation. Taken together with our findings in this prospective study, there is strong evidence for a causal relationship of factor XI variation with VTE risk. Presumably, the reason for this relationship is increased thrombin formation and perhaps fibrin stability 27 related to higher levels of factor XI, hypotheses that deserved further study.
There are two other studies of elevated factor IX and VTE risk. The LETS reported an odds ratio of 3.0, while a study of postmenopausal women in the UK reported an odds ratio of 2.3 for higher versus lower levels. In the current report, a weak unadjusted association of elevated factor IX with VTE was seen, but this association disappeared after adjustment for body-mass index, a correlate of higher factor IX and risk factor for VTE which was not considered in the previous studies. In terms of causation, factor IX polymorphisms have been inconsistently associated with VTE risk 25, 26, 28 , and factor IX gene variation has not been associated with factor IX levels in the context of VTE 28 .
Overall the findings suggest that, unless factor IX alterations are in the causal pathway between obesity and VTE, it is not a clinically relevant factor.
The LETS, the only study available, reported an odds ratio of 1.8 (95% CI 1.2-2.7) for factor X antigen above versus below the 90 th percentile, adjusting for age, sex and use of oral contraceptives 3 . This differs considerably from our findings, and in LETS the association was confounded by levels of vitamin K dependent factors. It is possible that changes in Factor X level after a VTE led to a spurious association in the case-control study compared to our prospective study, but other factors, such as a large number of contraceptive-related VTE in LETS, high within-person variability of factor X contributing to falsely null findings here, or assay differences could be considered. Finally, For personal use only. on October 31, 2017. by guest www.bloodjournal.org From the LETS analysis did not find associations of factor X gene variants with factor X levels 3 , further supporting no etiologic link of factor X with thrombosis.
The first reported case of factor XII deficiency was in John Hagemen, who died of a pulmonary embolus after a fracture 29 , leading to a hypothesis that factor XII deficiency causes VTE. The reasoning is that factor XII deficiency leads to impaired fibrinolysis 30 . In agreement with our findings, the first analysis of this question in a large study was by the LETS group, where there was no association of factor XII deficiency with thrombosis risk (OR 0.8 (95% CI 0.6-2.4)) 5 . Results from LETS and other studies included analyses of a polymorphism of the factor XII gene, 46 C T, which is associated with substantially lower factor XII levels. In two studies comprising 250 and 300 cases, and a study involving 81 Japanese cases, homozygosity for this polymorphism was about 3 to 3.5-fold more common among VTE cases than controls 7, 8, 31 . In one of these studies, factor XII deficiency was not significantly more common in cases than controls 7 . The LETS group 32 and a Brazilian case-control study of 189 cases 10 did not provide confirmation. More recently, a study evaluating a small number of pregnancy-associated thrombosis cases suggested a 6-fold higher risk of VTE with this polymorphism 9 . Gene discovery studies of VTE etiology to date, including one assessing haplotypes of factor XII 25 , have not corroborated these associations 26 . Given the mixed results from different populations, more work on factor XII and VTE risk is needed.
Only the LETS has investigated factor XIII A-subunit level and VTE risk 33 , where results were similar to those reported here. In a meta-analysis of retrospective studies involving 3165 cases, the factor XIII Val34Leu polymorphism, which is associated weakly with higher factor XIII activity but not with subunit levels, was inversely associated with VTE risk, but this was not confirmed in the subsequently published LITE study, which had the largest sample size of studies to date 12 . A mutation in the factor XIII B-subunit, the carrier for the factor XIII A-subunit, leads to increased dissociation of factor XIII in plasma and has also been related to modestly increased thrombosis risk 34 .
Strengths of our study include the prospective design, with coagulation factors almost always measured before occurrence of events. This features rules out reverse causality as an explanatory factor. Associations of factor XI with VTE risk were similar for near-term and longer-term time periods, strengthening our conclusions. Participants were followed frequently and careful ascertainment was used to validate VTE events. The study included two general population samples, although some participants, such as those in nursing homes and with advanced medical conditions, were excluded at baseline. Finally, there were a large number of cases, allowing ample power and some subgroup analyses. Limitations should also be considered. We know little about the withinperson variability of these coagulation factors, so that levels measured years before a VTE may not reflect levels closer to the time of the event. This could lead to underestimation of associations and an interpretation that associations of factor XI with VTE risk might be larger than we observed. We included participants who self-reported prior VTE in our analysis, however exclusion of these participants did not alter the findings. Finally, findings related to differential associations for DVT versus PE need to be interpreted cautiously, as case classification in this study might not be reliable.
In conclusion, among these procoagulant factors, only elevated factor XI was a risk factor for VTE in this study. More work on the epidemiology and genetics of factor XI in relation to VTE is needed, 
Figure 1. Odds ratios of venous thromboembolism by quintiles of coagulation factors.
Analyses were adjusted for age, sex, race and study. Diamond represent factor IX, squares factor X, triangles factor XI, open squares factor XII, circles factor XIII. Fifth quintile cutoffs for factors IX-XIII, respectively: 167, 161, 157, 179 and 171%.
